Revisiting Outcomes–Based Pricing Propositions for the PCSK9 Inhibitor Evolocumab | Cardiology | JAMA Internal Medicine | JAMA Network
[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 34.239.150.57. Please contact the publisher to request reinstatement.
1.
Sabatine  MS, Giugliano  RP, Wiviott  SD,  et al; Open-Label Study of Long-Term Evaluation against LDL Cholesterol (OSLER) Investigators.  Efficacy and safety of evolocumab in reducing lipids and cardiovascular events.  N Engl J Med. 2015;372(16):1500-1509.PubMedGoogle ScholarCrossref
2.
Kazi  DS, Moran  AE, Coxson  PG,  et al.  Cost-effectiveness of PCSK9 inhibitor therapy in patients with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease.  JAMA. 2016;316(7):743-753.PubMedGoogle ScholarCrossref
3.
Arrieta  A, Page  TF, Veledar  E, Nasir  K.  Economic Evaluation of PCSK9 inhibitors in reducing cardiovascular risk from health system and private payer perspectives.  PLoS One. 2017;12(1):e0169761.PubMedGoogle ScholarCrossref
4.
Institute for Clinical and Economic Review Final Report. PCSK9 Inhibitors for Treatment of High Cholesterol: Effectiveness, Value, and Value-Based Price Benchmarks. https://icer-review.org/wp-content/uploads/2016/01/Final-Report-for-Posting-11-24-15-1.pdf. Published November 24, 2015. Accessed June 12, 2017.
5.
Sabatine  MS, Giugliano  RP, Keech  AC,  et al; FOURIER Steering Committee and Investigators.  Evolocumab and clinical outcomes in patients with cardiovascular disease.  N Engl J Med. 2017;376(18):1713-1722. doi:10.1056/NEJMoa1615664PubMedGoogle ScholarCrossref
6.
Beasley D, Humer C. Reuters. Amgen discounts cholesterol drug, but payers want more. http://uk.reuters.com/article/us-heart-amgen-pricing-idUKKBN16O2P2. Published March 18, 2017. Accessed March 18, 2017.
Research Letter
September 2017

Revisiting Outcomes–Based Pricing Propositions for the PCSK9 Inhibitor Evolocumab

Author Affiliations
  • 1Department of Pharmacy and Therapeutics, School of Pharmacy, University of Pittsburgh, Pittsburgh, Pennsylvania
JAMA Intern Med. 2017;177(9):1388-1390. doi:10.1001/jamainternmed.2017.3143

The approval of the proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor evolocumab was based on the 61% reduction in the surrogate outcome of low-density lipoprotein cholesterol shown in clinical trials,1 which, based on the low-density lipoprotein hypothesis, was expected to translate into a 36% to 39% reduction in the risk of cardiovascular events.2 Under these conditions, Kazi et al2 and Arrieta et al3 predicted PCSK9 inhibitors would be cost-effective at an annual price of $4250 to $4500, and the Institute for Clinical and Economic Review recommended an annual price of $2177,4 estimates considerably lower than the price Amgen set for evolocumab($14 000). The results of the Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk (FOURIER) trial,5 powered to evaluate the efficacy of evolocumab in preventing cardiovascular events, were recently published. In the FOURIER trial,5 evolocumab was associated with a 27% and 21% reduction in the risk of myocardial infarction (MI) and stroke, respectively. There was no reduction in cardiovascular death or all-cause mortality. Following the publication of these results, which failed to meet the expectations generated by previous predictions,2 Amgen announced its willingness to engage in contracts where the cost of evolocumab would be refunded for patients who have an MI or a stroke while using the drug. In this article, I simulate the annual price of evolocumab under the outcome-based contracts proposed by Amgen, and put my estimates in the context of the available evidence on the cost-effectiveness of PCSK9 inhibitors.

×